Knight receives exclusive license to commercialize rigosertib in Canada Onconova eligible to receive up to CAD 33.95 million in clinical, regulatory, and sales-based milestones and tiered double-digit royalties NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.
Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to feature: biomarker genomic studies from pivotal INSPIRE Trial a novel adaptive trial design for a pivotal Phase 3 Study trial design
NEWTOWN, Pa., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), announced that the Company believes it remains
NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) , a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that it has entered into securities
NEWTOWN, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS) today announced that it has decided to terminate the
NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), will present at the RAS-Targeted Drug Discovery Summit
NEWTOWN, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today provided a corporate update and reported financial
The alliance will leverage Mission Bio’s Tapestri Platform to investigate Onconova’s novel cancer therapy rigosertib, through clinical trials NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics , Inc. (NASDAQ: ONTX) , a Phase 3 stage
Conference Call and Webcast at 9 a.m. Eastern Time on August 14, 2019 NEWTOWN, Pa., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on
NEWTOWN, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced two presentations at
NEWTOWN, Pa., May 28, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it will be
NEWTOWN, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS), today provided
Onconova to Receive $4 Million Upfront, including $2 Million Fee and $2 Million for Onconova Shares Purchased at a Premium, Plus up to $45.5 Million in Regulatory and Sales Milestones for Rigosertib in Greater China HanX to Dedicate $2 Million in Local Currency to Invest in Greater China Rigosertib
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, May 14, 2019 NEWTOWN, Pa., May 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug
NEWTOWN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced